Autophagy-mediated chemosensitization by cysteamine in cancer cells

Int J Cancer. 2011 Sep 1;129(5):1087-95. doi: 10.1002/ijc.25771. Epub 2011 Mar 25.

Abstract

Cysteamine (CS) has many biomedical and clinical applications because of its excellent water solubility, low cytotoxicity and good biocompatibility. A previous study by Brawer et al. reported the occurrence of many Gomori inclusion bodies in CS-treated astrocytes, which would suggest the induction of autophagy. Here we provided a comprehensive line of evidence demonstrating that CS caused autophagosome accumulation in cancer cells. CS exerted a biphasic effect on the autophagy process, increasing the formation of autophagosomes in the early phase and blocking the autophagic degradation in a later phase. Furthermore, we showed that CS sensitized doxorubicin-elicited chemotherapeutic killing in HeLa, B16 melanoma and doxorubicin-resistant MCF-7 cells and also enhanced chemotherapeutic efficacy of doxorubicin in a mouse melanoma model. Finally, we demonstrated that the chemosensitizing effect of CS was at least partly dependent on its ability to modulate autophagy. Our results revealed a novel biological function for CS in enhancing the chemotherapeutic effect of doxorubicin through autophagy modulation and pointed to the potential use of CS in adjunct cancer chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / pharmacology*
  • Autophagy
  • Cysteamine / pharmacology*
  • Doxorubicin / pharmacology*
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Synergism
  • Female
  • HeLa Cells
  • Humans
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / pathology*
  • Mice
  • Mice, Inbred C57BL
  • Tumor Cells, Cultured

Substances

  • Antibiotics, Antineoplastic
  • Cysteamine
  • Doxorubicin